THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) (UK MAR)

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR

THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT)

REGULATIONS (SI 2019/310) (UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED

TO BE IN THE PUBLIC DOMAIN.

OKYO Pharma Announces Activation of First Clinical

Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease

London and New York, NY, April 25, 2023 - OKYO

Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is developing

OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, today announces the activation

of the first clinical trial site in the U.S. for its phase 2, multi-center, randomized, double-blinded, placebo-controlled trial, evaluating

the efficacy and safety of OK-101 ophthalmic solution in subjects with dry eye disease. First patient first visit is presently

expected to occur within the next two weeks.

"Our primary focus continues to be on advancing

the clinical development of OK-101 as a potential treatment option for dry eye disease, a chronic ocular condition that affects roughly

700 million people worldwide," said Gary S. Jacob, Ph.D., CEO of OKYO Pharma. "With the activation of our first clinical site

we are now very close to the opening of the OK-101 phase 2 trial and are looking forward to initiating enrollment and completing the trial

before the end of the year."

OK-101 is a lipid conjugated chemerin peptide antagonist

of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response.

OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce a novel long-acting drug candidate for treating dry

eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal

neuropathic pain; and is designed to combat washout through the inclusion of the lipid anchor' contained in the candidate

drug molecule to enhance the residence time of OK-101 within the ocular environment.

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a

life sciences company admitted to listing on NASDAQ and on the standard segment of the Official List of the UK Financial Conduct Authority

and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development

of novel molecules to treat inflammatory dry eye diseases and chronic pain. For further information, please visit www.okyopharma.com.

Forward-Looking Statements

Certain statements made in this announcement are forward-looking

statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations,

estimates, and projections about its industry; its beliefs; and assumptions. Words such as anticipates,' expects,'

intends,' plans,' believes,' seeks,' estimates,' and similar expressions

are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known

and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and

could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions

security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view

of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events

as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates

to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement

except as required by law or by any appropriate regulatory authority.

For further information, please visit the Company's

website at www.okyopharma.com

The person who arranged for the release of this announcement

on behalf of the Company was Gary S. Jacob, Ph.D., Chief Executive Officer of OKYO.